Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease

Psychiatry Clin Neurosci. 1998 Apr;52(2):198-200. doi: 10.1111/j.1440-1819.1998.tb01028.x.

Abstract

For insomniac patients, sleeping drugs are used: in addition, concomitant therapy with other drugs has been tried in an effort to prevent a decrease in the effects due to long-term continuous use. This report presents the results of a study on the sleeping effects in nine aged patients with insomnia associated with cerebrovascular and noncerebrovascular disorders who received concomitant therapy with Zopiclone and Aniracetam. The treatment in 7/9 cases (78%) was found to be effective, showing more than 50% prolongation of sleeping time, and in two cases (22%) was found to be ineffective. We discuss the mechanism of action referring to the literature.

Publication types

  • Review

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Atrophy
  • Azabicyclo Compounds
  • Cerebral Cortex / pathology*
  • Cerebral Infarction / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypnotics and Sedatives / administration & dosage*
  • Hypnotics and Sedatives / adverse effects
  • Male
  • Nootropic Agents / administration & dosage*
  • Nootropic Agents / adverse effects
  • Parkinson Disease / drug therapy*
  • Piperazines / administration & dosage*
  • Piperazines / adverse effects
  • Polysomnography
  • Pyrrolidinones / administration & dosage*
  • Pyrrolidinones / adverse effects
  • Sleep Initiation and Maintenance Disorders / drug therapy*
  • Sleep Stages / drug effects

Substances

  • Azabicyclo Compounds
  • Hypnotics and Sedatives
  • Nootropic Agents
  • Piperazines
  • Pyrrolidinones
  • zopiclone
  • aniracetam